28th Aug 2013 12:46
28/8/2013
Immunodiagnostic Systems Holdings plc (the "Company")
Additional Listing
Application has today been made to AIM for admission of 90,970 new Ordinary Shares of 2 pence each in the Company ("Shares"). These Shares, which will rank pari passu in all respects with the existing shares in issue, have today been allotted pursuant to the exercise of options under the Company's Unapproved Share Option Scheme.
Admission is expected to become effective on 3 September 2013. Following admission to trading of the Shares, the Company will have 29,006,331 Ordinary Shares of 2 pence each in issue.
For further information:
Immunodiagnostic Systems Holdings plc | Tel : +44 (0)191 5190660 |
Patrik Dahlen, Chief Executive Officer | |
Chris Yates, Finance Director | |
Peel Hunt LLP | Tel : +44 (0)207 418 8900 |
James Steel | |
Dr Vijay Barathan | |
FTI Consulting | Tel : +44 (0)207 831 3113 |
Ben Atwell | |
Simon Conway | |
Mo Noonan |
About Immunodiagnostic Systems Holdings PLC
The Group operates in the in-vitro diagnostics ("IVD") market by designing, manufacturing and selling immunoassay kits as well as its automated analyser, the IDS-iSYS System. The IDS product range is used to measure or detect particular substances within a sample, thus aiding the diagnosis or monitoring of a disease or providing information for research studies.
Related Shares:
IDH.L